Bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma
The Department of Health has asked the Institute to conduct an appraisal of bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma. The Institute has now been informed by the company that it will no longer be pursuing a licensing application for bendamustine in this indication. Therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any developments.
 
Status Suspended
Process STA
Referral date 01 May 2012
Topic area
  • Cancer
Description

Scoped as part of Batch 22

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: Bijal Joshi
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
19 May 2016 Suspended, The Department of Health has asked the Institute to conduct an appraisal of bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma. The Institute has now been informed by the company that it will no longer be pursuing a licensing application for bendamustine in this indication. Therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any developments.
4 February 2013 The manufacturer is unable to provide an evidence submission for this appraisal by 22 February 2013. The appraisal is suspended whilst we consider the next steps.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance